CCNE1 and endometrial cancer: In vitro and in vivo studies have reported sensitivity of UCS cell lines to the ATR inhibitor elimusertib, and a separate study has reported synergy between Wee1 and ATR inhibition in CCNE1-amplified ovarian and endometrial cancer models (Manavella et al., 2023).